Pancreatic tumor patients could be stratified based on MAP17 expression to receive a combination treatment of current agents with NAMPT inhibitors, which seems to sensitize cells to traditional treatments only in tumors with high MAP17 expression. Here, NAMPT is linked to pancreatic neoplasm.